You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Details for Patent: 9,290,504


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,290,504 protect, and when does it expire?

Patent 9,290,504 protects CALQUENCE and is included in two NDAs.

This patent has eighty-one patent family members in forty-one countries.

Summary for Patent: 9,290,504
Title:4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
Abstract: The present invention relates to 6-5 membered fused pyridine ring compounds according to formula (I) or a pharmaceutically acceptable salt thereof or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of 6-5 membered fused pyridine ring compounds according to formula I in the treatment of Brutons Tyrosine Kinase (Btk) mediated disorders. ##STR00001##
Inventor(s): Barf; Tjeerd A. (Ravenstein, NL), Jans; Christiaan Gerardus Johannes Maria (Cuijk, NL), Man; Petrus Antonius De Adrianus (Hurwenen, NL), Oubrie; Arthur A. (Wijchen, NL), Raaijmakers; Hans C. A. (Eindhoven, NL), Rewinkel; Johannes Bernardus Maria (Berghem, NL), Sterrenburg; Jan-Gerard (Renkum, NL), Wijkmans; Jacobus C. H. M. (Oss, NL)
Assignee: Merck Sharp & Dohme B.V. (Haarlem, NL)
Application Number:14/233,418
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,290,504
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 9,290,504

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca CALQUENCE acalabrutinib CAPSULE;ORAL 210259-001 Oct 31, 2017 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Astrazeneca CALQUENCE acalabrutinib maleate TABLET;ORAL 216387-001 Aug 3, 2022 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,290,504

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
11174578Jul 19, 2011
PCT Information
PCT FiledJuly 11, 2012PCT Application Number:PCT/EP2012/063552
PCT Publication Date:January 24, 2013PCT Publication Number: WO2013/010868

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.